Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC5RL7)

Drug Name

DNX-2000 Drug Info

Synonyms

SYK kinase inhibitor (autoimmune disorders), Dynamix/Teva Pharmaceutical

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostamatinib	DM6AUHV	Immune thrombocytopenic purpura	3B64.13	Approved	[1]
Fostamatinib disodium	DM3274D	Thrombocytopenia	3B64	Phase 3	[2]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[3]
TAK-659	DMJH3U0	Diffuse large B-cell lymphoma	2A81	Phase 2	[4]
GS-9876	DM9Q2B6	Cutaneous lupus erythematosus	EB5Z	Phase 2	[5]
GS-9973	DMKWCTR	Acute myeloid leukaemia	2A60	Phase 2	[6]
Cevidoplenib	DM9QU5G	Rheumatoid arthritis	FA20	Phase 2	[7]
HM43239	DMV1SDA	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SKI-O-703	DMTSKXR	Rheumatoid arthritis	FA20	Phase 1	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Company report (Portola Pharmaceuticals)
4	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
7	A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
8	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
9	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.